Results 121 to 130 of about 769 (187)

Accelerating Drug Development in Hormone-Naïve Prostate Cancer through Multimodal Therapy Strategies: The MetaCURE Phase 2 Randomized Clinical Trial. [PDF]

Clin Cancer Res
McHugh D, Dallos M, Teo MY, McBride SM, Gopalan A, Arfe A, Gaffney CD, Amjed M, McCann PJ, Benoliel H, Autio KA, Goh AC, DeRudder K, Ryan CJ, Szmulewitz RZ, Morgans AK, Bubley GJ, Gupta S, Klein EA, Nguyen PL, Kibel AS, Wagner AA, Kaplan ID, Eggener S, Einstein DJ, Acosta AM, Tendulkar R, VanderWeele DJ, Catalona W, Sachdev S, Liauw SL, Eastham JA, Taplin ME, Scher HI.   +33 more
europepmc   +1 more source

Outcomes for [¹⁷⁷Lu]Lu-PSMA-617 with and Without Concurrent Use of Androgen Receptor Pathway Inhibitors in Patients with Metastatic Castration-resistant Prostate Cancer. [PDF]

Eur Urol Oncol
Muniz M, Sartor O, Orme JJ, Koch RM, Scharf Z, Heath EI, Zarka JG, Kase AM, Riaz IB, Andrews JR, Thorpe MP, Tuba Kendi A, Bilgin GB, Johnson GB, Kwon ED, Childs DS.   +15 more
europepmc   +1 more source

Real-world clinical usage and efficacy of apalutamide in men with nonmetastatic castration-resistant prostate cancer: a multi-institutional study in the CsJUC. [PDF]

Jpn J Clin Oncol
Tohi Y, Kobayashi K, Daizumoto K, Sekino Y, Fukuhara H, Niigawa H, Katayama S, Shimizu R, Takamoto A, Nishimura K, Nagami T, Hayashida Y, Hirama H, Shiraishi K, Tomida R, Kobatake K, Inoue K, Miyaji Y, Bekku K, Morizane S, Miura N, Wada K, Sugimoto M, Chu-shikoku Japan Urological Consortium .   +23 more
europepmc   +1 more source

Real-world clinical outcomes of apalutamide versus abiraterone with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer. [PDF]

Int J Clin Pharm
Pons-Fuster E, Gonzalez-Ponce CM, Ros-Martinez S, Fernández-Ávila JJ, Díaz-Carrasco MS, Espuny-Miró A.   +5 more
europepmc   +1 more source

Dermatological adverse events in Chinese prostate cancer patients treated with the androgen receptor inhibitor apalutamide. [PDF]

Front Immunol
Wang Q, Ren ZT, Wu HF, Gu HC, Li XW, Tang ZL.   +5 more
europepmc   +1 more source

Pharmacist Intervention in Outpatients With Prostate Cancer Prevents Apalutamide-induced Skin Adverse Events. [PDF]

In Vivo
Umehara K, Saito Y, Takada S, Yamagishi K, Takada N, Maruyama S, Harabayashi T, Hashishita H.   +7 more
europepmc   +1 more source

Systemic treatment of metastatic castration-sensitive prostate cancer: A meta-analysis of efficacy and safety. [PDF]

Medicine (Baltimore)
Zhang M, Wan L, Yao Y, Wu R, Li W, Gu P.
europepmc   +1 more source

Multicenter Real-World Study: 432 Patients with Apalutamide in Metastatic Hormone-Sensitive Prostate Cancer. [PDF]

Curr Oncol
Encarnación Navarro JA, Morillo Macías V, Borrás Calbo M, De la Fuente Muñoz I, Lozano Martínez A, García Martínez V, Fernández Fornos L, Guijarro Roche M, Amr Rey O, García Gómez R.   +9 more
europepmc   +1 more source

Impact of a rash management guide in patients receiving apalutamide for high-risk localized prostate cancer in the Apa-RP study. [PDF]

Prostate Cancer Prostatic Dis
Shore N, Hafron J, Saltzstein D, Bhaumik A, Aggarwal P, Phillips J, McGowan T.   +6 more
europepmc   +1 more source

Synthesis of Thiohydantoin. III

Synthesis of Thiohydantoin. III
openaire   +1 more source